VIDEO: RevOpsis prepares for first-in-human trials of RO-104
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease.
RO-104, the company’s lead candidate molecule, is a trispecific biologic designed to address VEGF-A, VEGF-C and Ang-2. As Healio previously reported, RevOpsis raised $16.5 million in a first seed funding round to advance clinical development of RO-104.
“With these backers, we feel confident going into first-in-human trials in the second half of next year,” Bhandari said.
Collapse
Bhandari R. RO-104: A novel trispecific monotherapy for retinal diseases. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Read more about